Close Menu

You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.

Home › Business, Policy & Funding › Business News › DarwinHealth Precision Cancer Tests Licensed by Encheng Group in China

DarwinHealth Precision Cancer Tests Licensed by Encheng Group in China

Dec 19, 2018
|
staff reporter

NEW YORK (GenomeWeb) — The Encheng Group said today that it has signed an agreement to acquire the exclusive commercial rights to DarwinHealth's precision cancer medicine tests in the Greater China region, which includes Hong Kong, Macao, and Taiwan.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sep
30
Featured Webinar

Moving from Non-Invasive Prenatal Screening to Prenatal Diagnostics: An Expert Panel Discussion

Sponsored by
LGC SeraCare Life Sciences

Non-invasive prenatal testing (NIPT) continues to expand globally to support maternal-fetal patient care. 

Oct
09
Featured Webinar

Navigating the FDA's EUA Process for Diagnostics in the Present and Future: A Stakeholder Panel Discussion

Sponsored by
PerkinElmer

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.

What's Popular?

In Molecular Diagnostics

  1. FDA Publishes First Batch of SARS-CoV-2 MDx Limit of Detection Comparison Results

    Premium

  2. Qiagen Acquires Remaining Stake in NeuMoDx Molecular for $248M

  3. FDA Grants Emergency Use Authorization to Coronavirus Tests From Visby Medical, SNIBE

  4. FDA Proposes Reclassification of Cytomegalovirus Quantitative Tests

  5. New York City Opening Dedicated COVID-19 Testing Laboratory

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.